Fresenius SE & Co. KGaA

Fresenius Announces FDA and EMA Acceptance for Review of Vedolizumab Biosimilar Candidate

BAD HOMBURG, Germany, July 31, 2026--Fresenius Kabi, an operating company of Fresenius, announced today that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to the reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration.

Yahoo Finance · 31/07/2026 · lire l'article ↗

Fresenius (XTRA:FRE) Stock May Still Be Cheap On Its 66% Run

Fresenius SE KGaA has delivered a 65.9% return over the past three years, yet the stock still screens as undervalued on Simply Wall St's broader checks, which raises the question of how much of that progress the current €44.78 share price is already reflecting. Over the last three years Fresenius SE KGaA returned 65.9%, which puts recent gains front and center when judging whether the current price still offers value. Plans for a more than €200 million Fresenius Ventures fund can support...

Yahoo Finance · 30/07/2026 · lire l'article ↗

Global Apheresis Market to Reach USD 4.41 Billion by 2031, Driven by Plasma-Based Therapies and Automated Technologies

Disposables lead the product segment, while plasmapheresis holds the largest procedure share. North America dominates the market. Key players include Terumo, Fresenius, Haemonetics, BD and B. Braun. Apheresis Market Apheresis Market Dublin, July 24, 2026 (GLOBE NEWSWIRE) -- The "Apheresis Market by Product, Procedure, Application, Technology, End User - Global Forecast to 2031" has been added to ResearchAndMarkets.com's offering. The global apheresis market is projected to grow from USD 3.02 bil

Yahoo Finance · 24/07/2026 · lire l'article ↗

Hikma and Fresenius best positioned from Trump's generic drug tariffs, says Citi

Hikma Pharmaceuticals PLC (LSE:HIK, OTC:HKMPF) and Fresenius Medical Care (NYSE:FMS) could emerge as relative winners from Donald Trump's proposed tariffs on generic drugs because of their extensive US manufacturing operations, according to Citi. The US president this week announced plans to...

Yahoo Finance · 23/07/2026 · lire l'article ↗

Fresenius establishes venture fund of more than €200 million to drive healthcare innovation

The issuer is solely responsible for the content of this announcement.

Yahoo Finance · 23/07/2026 · lire l'article ↗

Fresenius Medical Care dips after US proposes lower dialysis reimbursement rate

Investing.com -- Shares in Fresenius Medical Care (ETR:FMEG) fell about 5% Thursday after U.S. health regulator CMS proposed a smaller-than-expected increase to dialysis reimbursement rates and moved to bundle a key drug category into its payment system.

Yahoo Finance · 25/06/2026 · lire l'article ↗